BTBüşra Topuz Türkcan

Büşra Topuz Türkcan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Büşra Topuz Türkcan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effective Treatment of Pediatric Tongue Lymphangiomatosis with Sirolimus: A Case Report

    by Mehmet Azizoğlu, Büşra Topuz Türkcan, Nihat Atahan Kanbur, Sema Yılmaz

    Lymphangiomatosis, a rare condition characterized by the widespread development of lymphangiomas, often affects children under five years of age. Lymphangiomas, a type of lymphatic malformation, frequently manifest as cysts or lobulated masses in the head, neck, extremities, and trunk. While treatment options include observation, sclerotherapy, radiofrequency ablation, laser therapy, and surgery, the effectiveness can be limited. A 5-year-old girl was admitted to our department with a history of tongue enlargement, foul breath, bleeding, difficulty chewing, and impaired speech and nutrition. Upon physical examination, her tongue was noticeably enlarged, bluish in color, and covered with microvesicles and dark scabs. A diagnosis of microcystic lymphangioma of the tongue was confirmed through magnetic resonance imaging. Due to the inoperability of the lesion, propranolol 2 mg/kg/day was ordered for 3 months. But no improvement was seen. The patient was treated with sirolimus at a dosage of 1.8 mg/m²/day for six months. This treatment led to a noticeable reduction in lesion size. Subsequent follow-up visits, conducted every three months, revealed a significant improvement in all symptoms within one year. Treatment options for children with tongue lymphangioma are quite limited. Our findings demonstrate that sirolimus is a promising treatment option for this condition, with manageable side effects. We therefore advocate for prompt and efficient care and treatment with sirolimus in pediatric lymphangiomatosis to improve patient outcomes.

  • Open Access

    Evaluation of Retinal Toxicity in Pediatric Oncology Patients Receiving Platinum-Based Chemotherapy

    by Mehmet Ali Oktay, Ceyda Karadeniz, Hatice Tuba Atalay, Özge Vural, Arzu Okur, Faruk Güçlü Pınarlı, Ceyda Erişti Bölük, Büşra Topuz Türkcan, Tayyibe Sever, Aynur Oğuz

    Objective: Improved survival among pediatric oncology patients has increased the burden of late treatment-related complications, including retinal toxicity, a recognized acute and chronic effect of platinum chemotherapy. This study aimed to characterize retinal toxicity associated with platinum agents and compare the toxicities of cisplatin and carboplatin. Materials and Methods: Thirty-six pediatric patients (22 girls, 14 boys) who had completed platinum-based chemotherapy and were in remission were evaluated. Patients with pretreatment ocular disease or impaired renal function were excluded. Oncologic data and ophthalmologic findings including visual acuity, refractive errors, color vision, optical coherence tomography (OCT) (retinal nerve fiber layer thickness [RNFLT]; central foveal retinal thickness [CFRT]), and optical coherence tomography angiography (OCTA) (superficial capillary plexus [SCP]; deep capillary plexus [DCP]) vessel density were obtained retrospectively from medical records. Thirty-six age- and sex-matched healthy children without ocular or systemic disease served as controls. Results: Seventy eyes from the patient group and 72 from controls were analyzed. Time since last chemotherapy was negatively correlated with left-eye CFRT. Higher cumulative cisplatin dose was associated with reduced CFRT and thinning of RNFLT in the nasal-superior quadrant, while carboplatin dose showed no significant effect. Conclusion: Obvious retinal toxicity does not occur with platinum chemotherapy within the dos age range the patients received. The decrease in CFRT and RNFLT with a higher dose of cisplatin suggested that cisplatin may cause more retinal toxicity than carboplatin. The negative correlation between CFRT and duration since last chemotherapy suggests that RNFLT might get thinner over time; therefore, these patients need lifelong ophthalmologic follow-up.


  • Open Access

    Positron Emission Tomography Imaging and HScore-Based Diagnosis in Two Children with Malignancy-Associated Hemophagocytic Syndrome: Anaplastic Large-Cell Lymphoma and Precursor B-acute Lymphoblastic Leukemia

    by Zühre Kaya, Serap Kirkiz KayalI, Büşra Topuz Türkcan, Ümit Özgür Akdemir, Ahmet Bayramlı, Özge Vural, Nuket Yurur Kutlay, Ülker Koçak

    Cite this article as: Kaya Z, Kirkiz Kayalı S, Topuz Türkcan B, et al. Positron emission tomography imaging and HScore-based diagnosis in two children with malignancy-associated hemophagocytic syndrome: anaplastic large-cell lymphoma and precursor B-acute lymphoblastic leukemia. Turk Arch Pediatr. 2025;60(2):233-234.

  • Open Access

    Methotrexate-Mediated Arachnoiditis in a Child with Acute Lymphoblastic Leukemia

    by Sırma Karamercan, Zühre Kaya, Pınar Uyar Göcün, Büşra Topuz Türkcan, Merve Yazol, Öznur Boyunağa, Ülker Koçak